Pre-existing conditions: how they change the peptide calculus

Most peptide protocols you'll read assume a healthy adult baseline. If you have any of the conditions below, the math shifts — sometimes meaningfully. This guide tells you which conditions interact with which peptide classes and what to do.

Hypothyroidism (treated or untreated)

If you take levothyroxine or have known low thyroid:

• GH-axis peptides (Ipamorelin, CJC-1295, MK-677, Sermorelin, Tesamorelin) shift thyroid demand. Active GH-axis stimulation increases peripheral T4-to-T3 conversion and can unmask undertreated hypothyroid. Re-test TSH and free T3/T4 after 8-12 weeks of any GH-axis stack. You may need a levothyroxine dose adjustment.
• GLP-1s: most users tolerate fine. Some reports of TSH shifting on long-term tirzepatide. Re-test once after 90 days.
• Healing peptides (BPC-157, TB-500, GHK-Cu): no relevant interaction.

If thyroid is untreated and you have symptoms (fatigue, cold intolerance, weight gain, hair loss), get thyroid bloodwork done before starting any peptide. Otherwise you'll attribute thyroid symptoms to the peptide and chase the wrong intervention.

Prediabetes / insulin resistance / type 2 diabetes

GLP-1s are first-line and well-suited to this group — they're literally approved for type 2 diabetes (Ozempic, Mounjaro). Watch for:

• Hypoglycemia if you're already on insulin or sulfonylureas. Dose adjustment needed.
• Don't stop your existing diabetes medication without your doctor — especially insulin.

GH-axis peptides (MK-677 specifically, and at higher doses CJC/Ipamorelin) can transiently raise fasting glucose. If you have prediabetes, watch this with a CGM (Continuous Glucose Monitor — see /supplements/cgm-monitor). MK-677 is the one with the clearest documented glucose-elevating effect; some prediabetic users skip MK-677 specifically for this reason.

Healing peptides: no relevant interaction.

Hypertension (treated or untreated)

MT-1 and MT-2 can transiently raise blood pressure. If you're on antihypertensives, monitor BP at home for the first week. Some users see no change, some see modest increases.

GLP-1s: actually mildly blood-pressure-lowering for most users. Watch for orthostatic hypotension (lightheadedness on standing) in the early weeks if you're on multiple BP meds.

GH-axis peptides: minimal direct BP effect, but water retention from GH-axis activation can shift readings.

Salt-loaded electrolyte powders (used to manage GLP-1 fatigue) can be a problem if hypertensive. Pick low-sodium electrolyte options or skip them.

Anxiety disorders

Nootropic peptides (Selank, Semax) are often promoted as anxiolytic. Real-world: response is variable, and stacking with prescription SSRI/SNRI hasn't been studied. If you're on an SSRI, talk to your prescriber before adding anything serotonergic.

GLP-1s: most users feel fine or better. Some reports of low mood, particularly during dose escalations. If you have active anxiety with somatic symptoms (chest tightness, GI distress), GLP-1 nausea/early satiety can amplify those somatic concerns. Ramp slowly.

Caffeine + nootropic stacks: anxiety patients tolerate this poorly. Watch.

PCOS

GLP-1s (specifically tirzepatide, semaglutide) are increasingly used in PCOS for weight management and insulin sensitivity. Real-world results are good. Keep your endocrinologist or OB-GYN in the loop — labs (insulin, A1C, testosterone) should be tracked.

GH-axis peptides: less well-suited. PCOS is often associated with insulin resistance, and GH-axis stimulation can worsen that.

Hashimoto's / autoimmune thyroid

Same considerations as hypothyroid (above). Plus: peptides that modulate immune function (TB-500, Thymosin alpha-1) are studied in autoimmune contexts but the human data is limited. Talk to your doctor before stacking immune-modulating peptides on top of an autoimmune condition you're already managing.

History of skin cancer / family history of melanoma

MT-1 and MT-2: hard caution. Both stimulate melanocytes. Personal history of melanoma is a reasonable contraindication. Strong family history of melanoma — talk to your dermatologist before starting. New moles or changing moles during a cycle = stop and see a derm.

Pre-existing kidney disease

eGFR below 60 is the cutoff where peptide handling becomes unpredictable. Several peptides clear renally; reduced clearance means higher effective doses. This is doctor territory — don't run protocols off Pepdex data alone.

Pre-existing liver disease

Most peptides are injected and bypass first-pass liver metabolism, so the liver isn't the dose-handling chokepoint. Exceptions:

• Oral compounds (MK-677): liver does see meaningful exposure. Caution if liver enzymes are elevated.
• TUDCA (a supplement, not a peptide): can be supportive in fatty liver but not a substitute for medical management.

Cardiovascular history (heart attack, stroke, arrhythmia)

GLP-1s have shown cardiovascular benefit in trials (semaglutide, tirzepatide). They're generally cardioprotective. But if you have an active arrhythmia or history of stroke, run any new compound by your cardiologist first.

MT-1/MT-2 and high-dose GH-axis: more caution warranted. Increased blood pressure or fluid retention is a real concern in this population.

Pregnancy / breastfeeding / TTC

See When NOT to use peptides and Women's considerations. This is its own category, not just "another condition."

Active mental health crisis

Active suicidal ideation, recent psychiatric hospitalization, or unstable bipolar — this is the "stabilize the foundation first" category. Peptides can wait.

How to navigate when you have a condition

1. Get current labs done. You need a baseline. 2. Bring the peptide names to your doctor. They may not endorse, but they should weigh in. See Doctor conversation guide. 3. Start at the low end of any dose range. Conservative dosing during the first 4 weeks lets you isolate effect from interaction. 4. Track meticulously. Symptoms that overlap with your underlying condition need clear before/during/after data to interpret. 5. Re-test labs at 8-12 weeks. Your condition baseline may shift on the peptide. Adjust prescriptions if your prescriber agrees.

The general rule: if you have a chronic condition, you need more data — yours, regularly — than someone starting from a clean baseline. The peptides themselves are the same; the noise in your signal is higher, and the cost of misattribution is higher.